How many days does a course of vorasidenib-VORANIGO require and detailed instructions on dosage schedule and usage plan?

Vorasidenib (trade name VORANIGO) is an oral small molecule IDH1/2 inhibitor, mainly used to treat low-grade gliomas carrying IDH1 or IDH2 mutations. The drug selectively inhibits mutant IDH enzyme and reduces the accumulation of 2-hydroxyglutarate (2-HG), thereby inhibiting metabolic abnormalities and proliferation of tumor cells. Vorsidenib has shown significant molecular response and disease control effect in patients with low-grade glioma in clinical trials, and is one of the precision treatment options for IDH mutated brain tumors.

In terms of dosage schedule, it is usually recommended to take vorsidenib orally once a day, with the standard dose being 40mg/days. Patients need to take the medication strictly in accordance with the doctor's instructions to ensure stable blood concentration and maintain continued inhibition of the IDH mutated enzyme. According to the clinical trial design, a course of treatment usually takes 28 days as a cycle, with continuous daily medication. The course of treatment can be continued for several months or even longer depending on efficacy and tolerability, until the disease progresses or intolerable adverse reactions occur.

In the usage plan, it should be noted that the tablet of Voroxanib should be swallowed whole and should not be chewed or crushed. At the same time, the drug should be taken at a fixed time every day to reduce fluctuations in blood concentration. For patients with abnormal liver function, dose adjustment or treatment interval extension may be necessary to reduce drug-related toxicity. While taking the drug, patients need to regularly review blood biochemical indicators and brain imaging evaluation to monitor efficacy and potential side effects, including abnormal liver function, elevated blood lipids, or gastrointestinal reactions.

Overall, voroxanib (VORANIGO) is used in the treatment of IDH mutant low-grade gliomas The regimen is 40 mg taken orally once a day. The standard course of treatment is 28 days as a cycle. The drug is taken continuously until efficacy evaluation or tolerance limit. Standardized dose management, regular follow-up visits and laboratory monitoring are important guarantees to ensure the efficacy and safety of drugs, which can provide patients with sustained and stable anti-tumor effects while minimizing the risk of side effects.

Keyword tags:

Vorasidenib,Vorasidenib, VORANIGO, IDH1/2Inhibitors, low-grade glioma, treatment duration, dose

Reference materials:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038409/